FDA: Decision Expected on Ophthalmic Bevacizumab (Lytenava) for AMD Treatment
The Formal Dispute Resolution (FDR) process for the biosimilar application (ONS-5010/Lytenava) has concluded, and the company awaits the FDA's verdict. If approved, this would be the first FDA-approved ophthalmic formulation of bevacizumab for treating wet age-related macular degeneration (AMD), filling a critical gap in treatment access.
The Third FDA 'No' and a Chance for 'Yes': Why Lytenava Became a Hostage of Regulatory Anomaly in a $16 Billion Market
The Core: What's Really Happening
The Lytenava story is not about clinical failure. It's about a regulatory paradox that has become evident now, as Outlook Therapeutics has completed the Federal Dispute Resolution (FDR) process with the FDA and awaits a formal response in May 2026.
At first glance, it looks like another rejection. The FDA has already issued Complete Response Letters (CRL) three times—in August 2023, August 2025, and December 2025—for the ONS-5010/Lytenava application for wet AMD. The reason remains consistent: the agency requires "confirmatory evidence of efficacy" without specifying what exactly is needed. Meanwhile, the regulator acknowledges that the only adequate and well-controlled study (NORSE TWO) demonstrated efficacy. Safety has never been questioned.
What's the paradox? The drug is already approved in the UK and EU. NICE, the British watchdog for cost-effectiveness, not only approved Lytenava for the NHS but stated that clinical data show superiority over ranibizumab (Lucentis) and comparable efficacy to aflibercept (Eylea) and faricimab (Vabysmo). The drug has been commercially available in Germany and the UK since June 2025.
In other words: European regulators and NICE found the evidence convincing, while the FDA did not. This is not a scientific dispute. It's a regulatory anomaly rooted in the unique situation of the US market.
Timeline and Context
To understand the nature of this anomaly, we need to go back 20 years.
Since 2005, US ophthalmologists have used bevacizumab (Avastin) off-label for AMD. The drug is approved for oncology, not ophthalmology. Ophthalmologists obtain it from compounding pharmacies that repackage oncology vials into small syringes for intravitreal injections.
This practice became the de facto standard for one reason: price. One off-label bevacizumab injection costs about $50–100. For comparison: aflibercept (Eylea) is about $1,850, ranibizumab (Lucentis) around $2,000. With tens of millions of injections annually, the cost difference for Medicare amounts to billions of dollars.
Outlook Therapeutics attempted to resolve this anomaly legally: create an ophthalmic formulation of bevacizumab manufactured under GMP standards specifically for intravitreal injection, with an FDA-approved label and pharmacovigilance. The company's logic: physicians would prefer a legal product with guaranteed quality over an off-label drug from a compounding pharmacy with variable concentration.
The FDA responded with three CRLs.
First (August 2023): manufacturing issues and lack of "substantial evidence." Second (August 2025): after NORSE EIGHT, a non-inferiority study against ranibizumab, failed to meet its primary endpoint at week 8. Third (December 2025): despite additional data, the FDA again repeated the requirement for "confirmatory evidence of efficacy."
On April 7, 2026, Outlook filed a formal Formal Dispute Resolution Request (FDRR). The FDA accepted it and held a meeting in April. A formal response is expected in May.
Important nuance: FDR is an escalation. The company is no longer talking to the Division of Ophthalmology that issued the CRL. It is talking to the Office of New Drugs—a higher authority that can overturn the decision. This is the last pre-litigation mechanism.
Who Wins and Who Loses
Winners:
- Outlook Therapeutics (NASDAQ: OTLK) — if FDR succeeds. The company trades with a market cap of only $26–33 million. This is below the licensing fees it already receives from European sales. Any positive signal from the FDA could multiply the stock's value—not because the market is irrational, but because the current valuation assumes almost zero probability of US approval. Meanwhile, the drug is already on the European market, generating revenue, and the FDA has no safety concerns.
- Retina specialists tired of the status quo. Professor Tim Jackson from King's College Hospital put it precisely: "We value the ability to use products that meet the standards required for a marketing authorization. Controlled pharmaceutical manufacturing would alleviate concerns that compounding pharmacies increase the risk of rare but potentially devastating endophthalmitis."
- Medicare and insurers — paradoxically. Lytenava will not be cheaper than off-label bevacizumab from compounding pharmacies. NICE set a price of £470 per vial—"comparable to the cost of aflibercept." But a legal product removes legal risks associated with off-label use and potentially reduces costs from treating complications caused by unstable quality of compounded drugs.
Losers:
- Manufacturers of expensive anti-VEGF drugs—Bayer, Novartis, Roche. These companies have profited for decades from the anomaly: their drugs ($1,850–2,000 per injection) competed with off-label bevacizumab ($50–100) while maintaining market share due to their formal status as "the only approved options." The arrival of an officially approved ophthalmic bevacizumab at a significantly lower price redefines the market. That's why Bayer, Novartis, and Roche filed legal challenges attempting to block off-label bevacizumab use in the NHS.
- Compounding pharmacies. Their business of repackaging oncology Avastin into ophthalmic syringes exists solely due to the regulatory vacuum. Approval of Lytenava eliminates that vacuum.
- David Eichenbaum, MD—and those who share his view. In a commentary for Ophthalmology Times, he stated: Outlook's experience makes US approval of ONS-5010 unlikely and that other manufacturers are unlikely to attempt creating an ophthalmic bevacizumab formulation. This sentiment among part of the retina community—"it works, don't touch it"—if followed by the FDA, would preserve the status quo.
What the Media Isn't Saying
The main non-obvious insight: The FDA is caught between science and politics. The agency has no scientific grounds to deny approval: efficacy was shown in NORSE TWO, safety is uncontested, and European regulators and NICE—organizations with equally strict standards—approved the drug. But the FDA cannot ignore the consequences of its decision.
Approving Lytenava legitimizes bevacizumab as an ophthalmic drug. This would instantly redefine the standard of care for AMD. Why should Medicare pay $1,850 for aflibercept when an FDA-approved biosimilar costs $500? The question is rhetorical. The answer is a reshuffling of the $16 billion annual anti-VEGF therapy market.
The FDA cannot say this out loud. So it says: "we need additional confirmatory efficacy data," without specifying what. The company provides data—the FDA says "that's not the right data." This is a classic moving target.
Second insight: FDR is not just about Lytenava. It's a test of the Federal Dispute Resolution mechanism itself. If the Office of New Drugs upholds the Division of Ophthalmology, it signals to the industry that FDR is a ritual procedure incapable of overturning a division's decision. If the Office of New Drugs sides with the company, it sets a precedent that changes the balance of power between the FDA and sponsors.
Third unspoken point: In Europe, Lytenava is launched in partnership with Cencora (formerly AmerisourceBergen). This is not just a logistics partner. Cencora is one of the largest pharmaceutical distributors in the US. If the FDA approves Lytenava, Outlook already has an infrastructure partner for an immediate US launch. This isn't mentioned in press releases, but logistical readiness is a key factor in commercialization speed.
Fourth point—the FDA's silence on safety. None of the three CRLs cite safety issues. This is abnormal for three consecutive rejections. Usually, a safety signal is the main reason for a CRL. Here, safety is clean, efficacy is shown, CMC issues are resolved—yet rejection still comes. This reinforces the theory of non-scientific reasons for FDA resistance.
Forecast: Next 30 Days and 90 Days
30 days (by June 9, 2026):
- The FDA will issue a formal response to the FDR. Two scenarios. First (30% probability): The Office of New Drugs agrees with the company's position, initiating a BLA review process with specific guidance on what data is needed for approval. Second (70% probability): The FDA upholds the Division of Ophthalmology's position, leaving Outlook with a choice—conduct a new clinical trial or exit the US market.
- OTLK stock will react dramatically. In a positive scenario, rise to $1.00–1.50 (market cap $80–120 million). In a negative scenario, fall below $0.20.
- Regardless of the FDR outcome, Outlook will continue European expansion. Next markets after Germany and the UK are likely France and Italy.
90 days (by August 7, 2026):
- If FDR succeeds: Outlook will prepare a fourth BLA submission with clearly defined FDA requirements. The company may conduct a limited additional study or present real-world evidence from Europe. Potential approval shifts to 2027.
- If FDR fails: Outlook will likely abandon its solo fight for the US market and focus on Europe. A partnership with a major player (e.g., Regeneron or Biogen) with resources for a new study and political clout for FDA dialogue is possible.
- European sales of Lytenava will become the key driver of company value. At £470 per vial and a target market of 40,000 patients annually in the UK alone, European annual revenue could reach $50–80 million within 2–3 years.
- The US anti-VEGF therapy market will begin to change regardless of Lytenava's fate. The federal government, seeing European experience, may initiate its own cost-reduction mechanisms—for example, through the Medicare Drug Price Negotiation Program.
Fundamental conclusion: Lytenava is a mirror reflecting the systemic contradictions of the US pharmaceutical market. The drug has proven efficacy and safety. It is approved in other jurisdictions with equally strict regulatory standards. The only thing standing between it and American patients is not science, but economics. The FDA's decision following the FDR in May 2026 will answer a question that extends far beyond one drug: Is the US regulator ready to put patient and healthcare system interests above market status quo?
— Editorial Team
